Utilizing RT-PCR for infectious disease diagnosis with emphasis on non-tuberculous mycobacteria in Bangladesh, 2019–2024 Authors: Md Abu Sayem, Md Akram Hossain, Md Abdus Salam, Ayesha Ahmed Khan, Sourav Nath, Mohammad Amir Hossain, Md Ibrahim Adham, Md Ahshanul Haque Published: 2026 ABSTRACT AbstractBackgroundAdvanced diagnostics like reverse transcription polymerase chain reaction (RT-PCR) improve accuracy, limit infectious disease transmission and decrease mortality. This study evaluated the utility of RT-PCR for detecting infectious agents, including Nontuberculous mycobacteria (NTM), to guide clinical decision-making.MethodsThis retrospective study analyzed infectious disease data from Apollo Imperial Hospitals Ltd., Chattogram, Bangladesh from June 2019 to July 2024. Of 810 anonymized records extracted from the molecular biology laboratory, 786 samples with complete diagnostic information undergoing RT-PCR testing were included. Associations between positivity and socio-demographic/clinical factors (e.g., gender, sample type, pathogen tested) were analyzed using chi-square tests and binary logistic regression.ResultsAmong 786 patients, the mean age and SD was 38.8 ± 19.3 years with 87.1% adults or elderly (> 60 years old), and 53.7% were female. Samples comprised blood (31.6%), tissue (27.2%), body fluids (19.3%), swabs (8.1%), sputum (6.1%), pus (4.8%), and urine (2.8%). Overall, 100 (12.7%) specimens were positive by RT-PCR. Mycobacteria were detected in 6.4%, including Mycobacterium tuberculosis (MTB; 2.9%) and nontuberculous mycobacteria (NTM; 3.5%). The gender and clinical samples had significant difference with unadjusted OR, while pathogens were significantly associated with tests results (adjusted OR: 0.16, 95% CI: 0.03–0.87; P < 0.05) respectively. Male patients and specimens tested for respiratory pathogen panel (RPP) had higher odds of positivity, while body fluid, tissue, HPV/HSV, and Mycobacterial samples had lower odds of positivity.ConclusionsRT-PCR is a reliable diagnostic tool with higher sensitivity (up to 95%) and specificity (up to 100%) for infectious diseases, with potential for greater optimization in Bangladesh, especially for NTM detection. Improved specimen selection and clinical practices can enhance positivity rates and reduce costs. The NTP should prioritize better NTM detection to prevent misdiagnosis and improper treatment. WHO global report on tuberculosis should highlight NTM to guide policy and management strategies.Clinical trial numberNot applicable.Keywords: RT-PCR, Infectious disease diagnostics, Clinical samples, Nontuberculous mycobacteria, Mycobacterium tuberculosis, Bangladesh Introduction Globally, infectious diseases remain a leading cause of morbidity and mortality, responsible for approximately one-quarter of annual deaths. Recent years have seen resurgences of respiratory infections (e.g., pneumonia), the COVID-19 pandemic, and outbreaks of vector-borne diseases like dengue [1–4]. Enteric infections causing diarrheal diseases are major contributors to childhood mortality, with rotavirus, Shigella, and Campylobacter ranking among the leading pathogens. In 2019, rotavirus accounted for 19% of global diarrheal deaths in children, followed by shigellosis and campylobacteriosis at 12% each [5]. Bloodstream infections caused nearly 3 million deaths globally, with ~ 26% attributable to gram-negative bacteria [6]. Infectious diseases are more prevalent in low- and middle-income countries (LMICs) due to prevailing conducive factors [7]. Bangladesh as one of the LMICs is facing a complex, evolving infectious disease burden, dominated by recurrent dengue outbreaks, acute respiratory infections, and diarrheal diseases [4, 8]. In 2025, Bangladesh reported over 102,000 dengue cases and 412 deaths, marking a severe outbreak that extended beyond urban areas and overwhelmed healthcare resources [9]. Bangladesh rank 7th among 30 high tuberculosis burden countries globally [10]. Nontuberculous mycobacteria (NTM) pose an additional critical challenge worldwide, including in Bangladesh. However, knowledge on NTM epidemiology, clinical burden, and antimicrobial susceptibility patterns in the country remains severely limited, with sporadic case reports and small-scale studies indicating rising isolation rates from respiratory and extra-pulmonary specimens amid diagnostic confusion with tuberculosis [11]. Tropical climate of Bangladesh also favors the persistence of malaria, lymphatic filariasis, helminthiases, viral hepatitis, diarrheal diseases, and cholera [12–14]. Accurate and timely identification of infections is crucial for reducing morbidity, costs, enabling prompt treatment, and informing public health responses. Molecular diagnostics have transformed infectious disease detection worldwide, with real-time reverse transcription polymerase chain reaction (RT-PCR) established as the gold standard for pathogen identification in clinical settings [2]. In Bangladesh, both public and private hospitals expanded molecular laboratory capacities during large-scale outbreaks, notably the COVID-19 pandemic. RT-PCR offers superior sensitivity (up to 95%), specificity (up to 100%), and precision, making it indispensable for confirming infections across diverse pathogens and informing clinical decision-making and patient management [15, 16]. Despite advances in molecular diagnostics, most Bangladeshi healthcare facilities continue to rely on conventional microbiological and serological methods, which suffer from low sensitivity, prolonged turnaround times, and limited ability to detect emerging pathogens [14]. RT-PCR adoption has markedly enhanced diagnostic precision by detecting specific genetic sequences at low concentrations, proving invaluable for early or atypical infections. It identifies diverse agents including viruses, fungi, Mycoplasma, Chlamydia, atypical bacteria, and enteric pathogens such as Salmonella typhi and Salmonella paratyphi A [17, 18]. RT-PCR plays a crucial role in detecting diverse infectious diseases, including tuberculosis, HIV/AIDS, and pathogens responsible for sporadic, endemic, epidemic, and pandemic outbreaks. This study analyzed comprehensive records of patient’s socio-demographic, clinical, and laboratory data to correlate patient characteristics with RT-PCR-confirmed infectious diseases, identify key challenges, and provide policy recommendations for optimization. Materials and methods Study settings This retrospective study utilized secondary data from Apollo Imperial Hospitals Ltd., a 120-bed facility in Chattogram, Bangladesh, equipped with inpatient (IPD), outpatient (OPD), and emergency departments. The hospital has been utilizing RT-PCR since its inception in 2022 and maintains comprehensive records of patient socio-demographic, clinical, and laboratory data to monitor treatment outcomes and laboratory performance. The molecular biology laboratory, a key diagnostic unit, provided RT-PCR data for infectious diseases. Duty physicians referred IPD and OPD patients for laboratory workups, including RT-PCR when indicated. Test results were delivered to patients and routinely documented in the hospital’s medical records system. Data collection was approved by the appropriate authorities. Notably, diarrheal pathogen panels, encephalitis/meningitis panels, genitourinary panels, dengue, malaria, and other common pathogens were not assessed by RT-PCR due to low demand and availability of alternatives such as culture or rapid diagnostic tests (RDTs). Ethics approval and consent to participate The research utilized fully anonymized, publicly available secondary data from Apollo Imperial Hospital Ltd. in accordance with Helsinki declaration. As no primary data collection or identifiable human subjects were involved, informed consent was not required. The study was approved by the “Institutional Review Board (IRB)” of the Apollo Imperial Hospitals Ltd., Chattogram (Ref.: AIHL/IRB/20250605, dated 18th June 2025). Data processing maintained strict confidentiality, complying with data protection standards including anonymization protocols to prevent re-identification. No biological materials or clinical interventions were used. Samples Data on molecular diagnostics for infectious diseases from June 2019 to July 2024 were retrospectively collected from the hospital’s molecular biology laboratory. A total of 810 anonymized patient records were extracted; after excluding of incomplete entries, 786 samples data were used for analysis. Samples were categorized as follows: sputum, pus, urine; the cervical swab, wound, nasal, nasopharyngeal, and penile swabs were grouped as “swab” (n = 64); plasma, serum, and whole blood as “blood” (n = 248); pericardial, peritoneal, synovial, cerebrospinal, pleural, eye, gastric aspirate, mouth discharge, tracheal, bronchial, and other fluids as “body fluid” (n = 152); and granuloma, colon, breast, terminal ileum, excised block, cervical lymph node, skin scraping, neck tissue, fallopian tube, endotracheal, alveolar, endometrial tissues, fine-needle aspirate cytology (FNAC) material, bone marrow, and other tissues as “tissue” (n = 214). RT-PCR methods Multiplex RT-PCR assays were conducted using commercially available pathogen-specific kits validated for use on the Applied Biosystems QuantStudio 5 platform, with separate panels selected according to the target organism group, including viral hepatitis, herpesvirus infections, mycobacterial detection, and respiratory pathogens [19]. DNA was extracted from clinical specimens using a validated nucleic acid extraction protocol. Reactions were prepared using the recommended master mix, dispensed into optical PCR plates, and amplified under standard thermal cycling conditions, consisting of an initial denaturation step followed by 40–45 cycles. MTB/NTM detection was performed using a dedicated real-time PCR kit validated on the same platform. The assay differentiated Mycobacterium tuberculosis complex (MTBC) from nontuberculous mycobacteria (NTM) through dual-target amplification, with IS6110/IS1081 and the TbD1 region detected in the FAM channel for MTBC, and 16 S rRNA genus-specific amplification detected in the ROX channel for NTM. Fluorescence signals were collected at each cycle, and amplification curves were analyzed using the instrument software. An internal control (RNase P, Cy5) was included to verify nucleic acid extraction and amplification integrity. Thermal cycling consisted of 45 °C for 10 min, 95 °C for 3 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 60 s. Positive and negative controls were included in each run [20]. Inclusion and exclusion criteria All RT-PCR-requested samples by duty physicians from inpatient (IPD) or outpatient (OPD) departments, regardless of patient age or gender, were included. Samples requested for conventional tests were excluded. The patients from emergency department usually being transferred to IPD immediately after managing critical condition. Hence, there was no sample from emergency department. Data analysis Data were stored in Microsoft Excel and imported into SPSS (version 25.0) and Stata (version 14.0) for analysis. Entries were verified, cleaned, coded, and analyzed. Independent variables included age group, gender, patient source (IPD or OPD), sample type, and targeted infectious agent. The primary outcome was RT-PCR positivity. Associations were assessed using chi-square tests, and the selected variable which had significant (P < 0.05) differences were selected for binary logistic regression model to evaluate the independent factors associated with the outcomes. Statistical significance was set at P < 0.05. Results Of the 786 patients, 53.7% were female with adults (18–60 years) comprising the majority (58.7%), followed by elderly (> 60 years; 28.4%) and newborns to adolescents (13.0%). Most samples originated from outpatient department (OPD) (85.8%). Blood (31.6%) and tissue (27.2%) were the most common sample types, followed by body fluids (19.3%), swabs (8.1%), sputum (6.1%), pus (4.8%), and urine (2.8%). Mycobacterial testing predominated (66.0%), followed by HBV (19.2%), with fewer tests for other pathogens: tissue (HCV 3.2%), HPV (4.6%), HSV (2.4%), CMV (2.9%), and RPP (1.7%) (Table 1). Table 1Socio-demographic characteristics of patients and details of clinical samples tested by RT-PCR (n = 786)CharacteristicsFrequency% Age group < 18 years (Newborn to adolescents group)10213.018–60 years (Adult age group)46158.7> 60 years (Old age group)22328.4 Gender Male36446.3Female42253.7 Source of patient Inpatient department (IPD)11214.2Outpatient department (OPD)67485.8 Clinical samples Sputum486.1Pus384.8Urine222.8Swab648.1Body fluid15219.3Blood24831.6Tissue21427.2 Samples tested for Cytomegalovirus (CMV)232.9Hepatitis B virus (HBV)15119.2Hepatitis C virus (HCV)253.2Human Papillomavirus (HPV)364.6Herpes Simplex Virus (HSV)192.4Mycobacterium51966.0Respiratory Pathogen Panel (RPP)131.7 Socio-demographic characteristics of patients and details of clinical samples tested by RT-PCR (n = 786) The overall cumulative pathogen detection rate by RT-PCR was 12.7% across 786 clinical samples (Fig. 1). This low positivity likely reflects interlinked factors, including sample quality, physician-assessed clinical signs and symptoms, personnel training, and other factors. Pathogen detection rate by RT-PCR at Apollo Imperial Hospitals Ltd Mycobacteria testing dominated across most sample types, comprising 100% of sputum (n = 48), pus (n = 38), and tissue (n = 214) samples. Mycobacteria was tested among 87.5% of body fluids (n = 133), 36.4% of urine (n = 08), 25.4% of blood (n = 63), and 23.4% of swabs (n = 15) (Table 2). HBV testing was prominent in blood (60.9%), while swabs were tested for diverse pathogens: HPV (56.3%), RPP (20.3%), and mycobacteria (23.4%). CMV and HCV were detected primarily in urine, body fluid and blood respectively; HSV mainly in body fluids. Overall, mycobacteria testing accounted for 66.0% of all specimens tested (519/786), followed by HBV (19.2%) (Table 2). Table 2Frequency distribution of pathogens tested by RT-PCR across clinical sample types (n = 786); values represent counts (row percentages)Sample groupNumber (%)CMVHBVHCVHPVHSVMycobact.RPPSputum0 (00.0)0 (00.0)0 (00.0)0 (00.0)0 (00.0)48 (100.0)0 (00.0)Pus0 (00.0)0 (00.0)0 (00.0)0 (00.0)0 (00.0)38 (100.0)0 (00.0)Urine14 (63.6)0 (00.0)0 (00.0)0 (00.0)0 (00.0)8 (36.4)0 (00.0)Swab0 (00.0)0 (00.0)0 (00.0)36 (56.3)0 (00.0)15 (23.4)13 (20.3)Body fluid2 (01.3)0 (00.0)0 (00.0)0 (00.0)17 (11.2)133 (87.5)0 (00.0)Blood7 (02.8)151 (60.9)25 (10.1)0 (00.0)2 (00.8)63 (25.4)0 (00.0)Tissue0 (00.0)0 (00.0)0 (00.0)0 (00.0)0 (00.0)214 (100.0)0 (00.0)Total23 (02.9)151 (19.2)25 (03.2)36 (04.6)19 (02.4)519 (66.0)13 (01.7)Abbreviations. CMV: Cytomegalovirus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HPV: Human Papillomavirus, HSV: Herpes Simplex Virus, Mycobact.: Mycobacterium, RPP: Respiratory Pathogen Panel Frequency distribution of pathogens tested by RT-PCR across clinical sample types (n = 786); values represent counts (row percentages) Abbreviations. CMV: Cytomegalovirus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HPV: Human Papillomavirus, HSV: Herpes Simplex Virus, Mycobact.: Mycobacterium, RPP: Respiratory Pathogen Panel Pathogen detection rates varied significantly by gender (P < 0.05), with males showing higher positivity (15.7%) than females (10.2%). Detection also differed markedly across sample types (P < 0.01), with the highest rates in urine (22.7%), blood (21.0%), and swabs (15.6%), moderate rates in sputum (12.5%) and pus (10.5%), and lowest in body fluids (8.6%) and tissue (4.7%). Among pathogens, respiratory pathogen panel (RPP) exhibited the highest detection rate (76.9%), followed by HBV (28.5%), HCV (28.0%), and CMV (26.1%). HPV testing was negative across all 36 samples, HSV showed low positivity (5.3%), and Mycobacteria had the lowest rate (6.4% from 519 samples) (Table 3). Table 3Association between patient characteristics, sample types, pathogens, and RT-PCR positivity rates (n = 786)CharacteristicsTests results by RT-PCRP value Age group Detected (%)N = 100Not detected (%)N = 686< 18 years (Newborn to adolescents group)10 (9.8)92 (90.2)0.33318–60 years (Adult age group)56 (12.1)405 (87.9)> 60 years (Old age group)34 (15.2)189 (84.8) Gender 0.022Male57 (15.7)307 (84.3)Female43 (10.2)379 (89.8) Clinical samples for pathogen detection 0.001Sputum6 (12.5)42 (87.5)Pus4 (10.5)34 (89.5)Urine5 (22.7)17 (77.3)Swab10 (15.6)54 (84.4)Body fluid13 (8.6)139 (91.4)Blood52 (21.0)196 (79.0)Tissue10 (4.7)204 (95.3) Pathogens detected by RT-PCR 0.001CMV6 (26.1)17 (73.9)HBV43 (28.5)108 (71.5)HCV7 (28.0)18 (72.0)HPV0 (0.0)36 (100.0)HSV1 (5.3)18 (94.7)Mycobacterium33 (6.4)486 (93.6)RPP10 (76.9)3 (23.1) Sources of patients 0.078IPD20 (17.9)92 (82.1)OPD80 (11.9)594 (88.1)Abbreviations. CMV: Cytomegalovirus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HPV: Human Papillomavirus, HSV: Herpes Simplex Virus, Mycobact.: Mycobacterium, RPP: Respiratory Pathogen Panel, IPD: In-patient Department, OPD: Out-patient Department Association between patient characteristics, sample types, pathogens, and RT-PCR positivity rates (n = 786) Detected (%) N = 100 Not detected (%) N = 686 Abbreviations. CMV: Cytomegalovirus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HPV: Human Papillomavirus, HSV: Herpes Simplex Virus, Mycobact.: Mycobacterium, RPP: Respiratory Pathogen Panel, IPD: In-patient Department, OPD: Out-patient Department Male patients exhibited higher odds of test positivity than females (unadjusted odds ratio [OR]: 1.64, 95% confidence interval [CI]: 1.07–2.50; P < 0.05 and adjusted OR: 1.29, 95% CI: 0.79–2.11; P > 0.05. Compared to blood samples, body fluid and tissue samples showed 65% (unadjusted OR:0.35, 95% CI: 0.18–0.67; P < 0.05) and 82% (unadjusted OR: 0.18, 95% CI: 0.09–0.37; P < 0.01) lower odds of positivity respectively. However, after adjusted the OR, the value showed higher odds of positivity for both body fluid and tissue samples (adjusted OR: 4.94, 95% CI: 0.96–25.49; P > 0.05 and adjusted OR: 2.81, 95% CI: 0.52–15.33; P > 0.05) respectively. The combined HPV/HSV testing had 95% and 90% lower odds (unadjusted OR: 0.05, 95% CI: 0.01–0.47; P < 0.05 and adjusted OR: 0.10, 95% CI: 0.01–1.40; P > 05), and Mycobacterial testing showed 81% and 84% lower odds (unadjusted OR:0.19, 95% CI: 0.07–0.52; P < 0.01 and adjusted OR: 0.16, 95% CI: 0.03–0.87; P < 0.05) against CMV. Conversely, respiratory pathogen panel (RPP) detection had 9.4-folds and 12-folds higher odds (unadjusted OR:9.44, 95% CI: 1.92–46.35; P < 0.05 and adjusted OR: 11.80, 95% CI: 2.33–60.36; P > 0.05) than CMV (Table 4). Table 4Factors associated with test positivity among patients tested for target pathogens at Apollo Imperial Hospitals, 2019–2024IndicatorsUnadjusted OR (95% CI)p-valueAdjusted OR (95% CI)p-value Gender FemaleReferenceReferenceMale1.64 (1.07, 2.50)0.0231.29 (0.79, 2.11)0.302 Sample group BloodReferenceReferenceSputum0.54 (0.22, 1.34)0.1827.32 (1.23, 43.41)0.028Pus0.44 (0.15, 1.31)0.1406.45 (0.99, 42.13)0.052Urine1.11 (0.39, 3.15)0.8463.62 (0.51, 25.73)0.199Swab0.70 (0.33, 1.46)0.3410.79 (0.36, 1.73)0.557Body fluid0.35 (0.18, 0.67)0.0024.94 (0.96, 25.49)0.057Tissue0.18 (0.09, 0.37)0.0002.81 (0.52, 15.33)0.232 Tests for CMVReferenceReferenceHBV1.13 (0.42, 3.05)0.8123.25 (0.52, 20.24)0.206HCV1.10 (0.31, 3.95)0.8823.22 (0.44, 23.73)0.251HPV/HSV0.05 (0.01, 0.47)0.0080.10 (0.01, 1.40)0.087Mycobacteria0.19 (0.07, 0.52)0.0010.16 (0.03, 0.87)0.034RPP9.44 (1.92, 46.35)0.00611.8 (2.33, 60.36)0.992Abbreviations. CMV: Cytomegalovirus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HPV: Human Papillomavirus, HSV: Herpes Simplex Virus, Mycobact.: Mycobacterium, RPP: Respiratory Pathogen Panel Factors associated with test positivity among patients tested for target pathogens at Apollo Imperial Hospitals, 2019–2024 Abbreviations. CMV: Cytomegalovirus, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HPV: Human Papillomavirus, HSV: Herpes Simplex Virus, Mycobact.: Mycobacterium, RPP: Respiratory Pathogen Panel Analysis of samples for Mycobacterial detection revealed both Mycobacterium tuberculosis (MTB) and Nontuberculous mycobacteria (NTM). Notably, NTM exhibited a higher detection rate (3.5%) than MTB (2.9%) (Fig. 2). Detection rate of MTB and NTM at Apollo Imperial Hospitals Ltd. (n = 519) Discussion In this study, infectious disease prevalence was highest among the elderly (> 60 years). Older adults generally experience elevated rates of communicable diseases. A study in Pakistan similarly reported that ~ 39% of communicable disease mortality among older age groups was attributable to tuberculosis, diarrhea, cholera, and hepatitis [21]. In this study, patients aged > 60 years accounted for 28.4% of samples submitted for RT-PCR testing, underscoring the substantial infectious disease burden in this group. These findings align with Pakistani data reporting high communicable disease morbidity and mortality among older adults [22]. Outpatient department (OPD) samples comprised 85.8% of submissions, indicating a strong patient preference for ambulatory care over inpatient (IPD) services for infectious diseases. This pattern aligns with typical trends across Bangladeshi public and private facilities. A nationwide analysis (2017–2021) similarly showed OPD visits consistently exceeding IPD admissions, reflecting broader reliance on outpatient management [23]. Blood, tissue, body fluids, swabs, sputum, and urine were the predominant clinical samples submitted for RT-PCR testing, consistent with findings from prior reviews documenting similar specimen types for molecular diagnostics [24]. No stool samples were analyzed, likely reflecting low demand in this corporate hospital setting and availability of alternative diagnostics. HBV and Mycobacterial testing predominated (85.2% combined), consistent with patterns reported in prior studies [25, 26]. In our study, the overall pathogen detection rate by RT-PCR was 12.7%. This rate likely reflects multiple interdependent factors, including clinical presentation, physician expertise, sample collection/processing quality, laboratory detection proficiency, and result interpretation. Beyond facility reputation and diagnostic standards, cost-effectiveness considerations critically influence optimal detection rates, balancing institutional efficiency with patient access to care. A pathogen detection rate > 10% is generally considered optimal for clinical diagnostics, indicating effective screening and reliable protocols. Our finding aligns with a study reporting an 11% detection rate across 11 common pathogens using RT-PCR [27]. This study targeted six specific pathogens and one pathogen panel across seven sample types. Mycobacteria predominated (66.0% of samples), followed by HBV (19.2%). Prior research similarly emphasizes frequent RT-PCR use for HBV and MTB detection, reflecting consistent priorities in molecular diagnostics [28–30]. In this study, females provided more samples, yet males showed a higher pathogen detection rate. This may suggest initial clinical assessments underestimated symptoms in females. Interestingly, other studies report the opposite trend, with higher positivity rates in females [31]. These discrepancies in pathogen detection rates between genders arise from multiple factors. Immune responses differ, with variations in antibody production or inflammation patterns. Health-seeking behaviors also play a role, as females often seek care earlier despite milder symptoms. Physician suspicion may be lower for certain infections in females due to atypical presentations. Biological factors, including hormonal influences on pathogen replication or clearance, further contribute to this variability. These elements underscore the need for gender-specific diagnostic approaches in infectious disease management. In this study, most samples originated from body fluids, blood, and tissue, with blood exhibiting the highest pathogen detection rate. Less common samples like urine and swabs also showed elevated detection rates relative to sputum and pus. While blood, urine, and swabs may appear preferable for broad pathogen detection, specimen choice remains highly pathogen-specific due to varying microbial habitats in the body. RT-PCR showed strong performance for respiratory pathogen panels, HBV, HCV, and CMV detection. Success likely stemmed from precise symptom evaluation, suitable sample choices, and meticulous processing. Despite Bangladesh’s focus on cervical cancer prevention, zero HPV detections highlight a training gap for physicians in recognizing HPV signs and making timely referrals to boost early diagnosis. In this study on Mycobacteria, NTM detection rates unexpectedly surpassed those of MTB. This trend signals shifting epidemiology and enhanced diagnostics, including greater clinician awareness and RT-PCR’s improved NTM sensitivity. Both American Thoracic Society (ATS) and European Respiratory Society jointly establish the diagnostic criteria of NTM. Contributing factors likely include rising environmental exposures, an aging population, and more immunocompromised patients, all amplifying NTM prevalence [32]. NTMs are increasingly significant pathogens worldwide, particularly in regions with successful TB control and rising NTM cases. National Tuberculosis Control Program (NTP) often rely on sputum for AFB, Xpert MTB/RIF, culture and drug susceptibility testing [e.g. solid and liquid culture, line probe assay] and imaging for pulmonary tuberculosis and other related tests such as ultrasonography, biopsy, MRI, histopathology for extra-pulmonary tuberculosis to detect MTB, NTM, and resistance. Out of multiple diagnostic tools, Liquid culture (BACTEC MGIT), Xpert MTB/RIF, LPA are gold standard tuberculosis diagnostic tools. However, NTP often under detect and fail to report NTM cases to WHO, masking true prevalence [10]. A Chinese study of 717 low-bacterial-load patients reported 24% MTB and 2% NTM detections. Previously treated cases faced elevated false-positive risks, underscoring diagnostic challenges in such scenarios [33]. RT-PCR may offer advantages over GeneXpert in certain contexts, particularly for nuanced NTM detection. Both Bangladesh’s NTP and WHO often neglect NTM documentation and reporting, underestimating its burden. Although MTB spreads airborne while NTM is primarily waterborne, their mimicking symptoms may cause misdiagnosis and suboptimal treatment [34]. NTM infections demand distinct treatment regimens compared to MTB, involving specific antibiotics like macrolides and ethambutol. Accurate differentiation is vital to avert ineffective therapy, drug toxicity, and poor outcomes. Strengthening disease surveillance, physician education on modern diagnostics and protocols, follow-up monitoring, and systematic reporting might enhance patient care and reduce morbidity [35–37]. This study relied on secondary data from a single hospital, limiting comparative analyses. Selection bias represents a major limitation of this retrospective study, as patients were not randomly selected for microbiological testing. It precluded evaluation of socio-demographic associations and constrained pathogen diversity. Consequently, results lack generalizability and warrant cautious interpretation within these constraints. Despite its advantages, RT-PCR carries risks of lab errors in sample collection, nucleic acid extraction, and result interpretation, potentially undermining accuracy. Rigorous quality control, staff training, and strict adherence to standard operating procedures (SOPs) are essential to maximize its benefits in clinical settings. The Clinical and Laboratory Standard Institute (CLSI) guidelines emphasize sample integrity through uncontaminated collection, proper blood techniques, accurate labeling, and integration of physician-assessed clinical signs, all critical for reliable RT-PCR performance [38, 39]. Despite its limitations, this study effectively distinguished multiple pathogens across diverse sample types using RT-PCR. These results highlight the importance of selecting appropriate specimens and employing thorough diagnostic strategies to improve detection accuracy and inform clinical decisions in comparable hospital environments. Conclusions RT-PCR is a reliable and versatile diagnostic tool for identifying infectious pathogens, aiding timely and evidence-based treatment decisions. Selecting appropriate specimen types and aligning clinical skills with underlying diseases can enhance positivity rates while reducing diagnostic costs. RT-PCR holds substantial untapped potential for optimization in Bangladesh, particularly in infectious disease diagnostics. The National Tuberculosis Program (NTP) should prioritize efforts to enhance detection of missed NTM cases, thereby mitigating misdiagnosis risks, preventing inappropriate treatment, and improving national public health outcomes. Furthermore, the WHO Global Tuberculosis Report should address NTM to heighten global policy awareness. Highlighting NTM would guide policymakers toward implementing comprehensive strategies for its detection and management. Acknowledgements We gratefully acknowledge the hospital authorities for providing support and necessary approvals. Abbreviations American Thoracic Society Clinical and Laboratory Standard Institute Cytomegalovirus Fine Needle Aspiration Cytology Hepatitis B Virus Hepatitis C Virus Human Papilloma Virus Herpes Simplex Virus In-patient Department Institutional Review Board Low and Middle Income Countries Line Probe Assay Mycobacteria Growth Indicator Tube Mycobacterium Tuberculosis Non-tuberculous Mycobacteria National Tuberculosis Control Program Out-patient Department Odds Ratio Respiratory Pathogen Panel Reverse Transcriptase Polymerase Chain Reaction Standard Operating Procedure Author contributions Md. Abu Sayem and Md. Akram Hossain conceptualized the study. Md. Abu Sayem acquired, cleaned, coded, and analyzed the data; drafted the original manuscript. All authors (Md. Abu Sayem, Md. Akram Hossain, Md. Abdus Salam, Ayesha Ahmed Khan, Sourav Nath, Mohammad Amir Hossain, Md. Ibrahim Adham, and Md. Ahsanul Haque) reviewed and edited the manuscript, including methods and data analysis. Md. Abu Sayem revised and finalized the final version. Funding There was no funding from any source for this study. Data availability Data are available within the manuscript and with corresponding author. Declarations Ethics approval and consent to participate The research utilized fully anonymized, publicly available secondary data from Apollo Imperial Hospital Ltd., Chattogram, Bangladesh in accordance with Helsinki declaration. As no primary data collection or identifiable human subjects were involved, informed consent was not required. The study was approved by the “Institutional Review Board (IRB)” of the Apollo Imperial Hospitals Ltd., Chattogram (Ref.: AIHL/IRB/20250605, dated 18th June 2025). Data processing maintained strict confidentiality, complying with data protection standards including anonymization protocols to prevent re-identification. No biological materials or clinical interventions were used. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data are available within the manuscript and with corresponding author.